Adaptive Biotechnologies
JP Morgan Healthcare Conference, Day 2: Novartis, Relay, Erasca, Syndax, AstraZeneca, and More
On the second day, Novartis boasted of Kisqali's $8 billion potential, Relay said it's taking a PI3Kα inhibitor into Phase III, and Syndax talked about Revuforj in NPM1-mutant AML.
NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing
Doctors ordering NeoGenomics Compass test packages will have the option of including Adaptive's ClonoSeq minimal residual disease assay.
In Brief This Week: Qiagen, Care Access, Immix Biopharma, Atsena Therapeutics, Aspen Neuroscience
News items for the week of Jan. 6, 2025.
FDA Advisors Unanimously Support Using MRD to Expedite Multiple Myeloma Drugs Through Trials
Premium
ODAC members agreed that minimal residual disease can be a reliable biomarker for accelerated approval, but sponsors must provide confirmatory evidence of clinical benefit.
JP Morgan Healthcare Conference Day 2: Bluebird Bio, Ideaya, Revolution, Relay, and More
On the second day, companies developing precision medicines and tests discussed pipeline priorities and strategic options for their businesses.